{"id":"https://openalex.org/W4283589822","doi":"https://doi.org/10.3389/fimmu.2022.924542","title":"Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events","display_name":"Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events","publication_year":2022,"publication_date":"2022-06-27","ids":{"openalex":"https://openalex.org/W4283589822","doi":"https://doi.org/10.3389/fimmu.2022.924542","pmid":"https://pubmed.ncbi.nlm.nih.gov/35833116","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/9272907"},"language":"en","primary_location":{"id":"doi:10.3389/fimmu.2022.924542","doi":"https://doi.org/10.3389/fimmu.2022.924542","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2022.924542","pdf_url":null,"source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.3389/fimmu.2022.924542","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109479013","display_name":"Zhaoliang Huang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zhaoliang Huang","raw_affiliation_strings":["Research and Development Department, Akeso Biopharma Co., Ltd., Zhongshan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development Department, Akeso Biopharma Co., Ltd., Zhongshan, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075112156","display_name":"Xinghua Pang","orcid":"https://orcid.org/0009-0000-3643-6277","observed_orcids":["https://orcid.org/0009-0000-3643-6277"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xinghua Pang","raw_affiliation_strings":["Research and Development Department, Akeso Biopharma Co., Ltd., Zhongshan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development Department, Akeso Biopharma Co., Ltd., Zhongshan, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026327823","display_name":"Tingting Zhong","orcid":"https://orcid.org/0000-0002-1527-0797","observed_orcids":["https://orcid.org/0000-0002-1527-0797"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tingting Zhong","raw_affiliation_strings":["Research and Development Department, Akeso Biopharma Co., Ltd., Zhongshan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development Department, Akeso Biopharma Co., Ltd., Zhongshan, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Tailong Qu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tailong Qu","raw_affiliation_strings":["Research and Development Department, Akeso Biopharma Co., Ltd., Zhongshan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development Department, Akeso Biopharma Co., Ltd., Zhongshan, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075167478","display_name":"Na Chen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Na Chen","raw_affiliation_strings":["Research and Development Department, Akeso Biopharma Co., Ltd., Zhongshan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development Department, Akeso Biopharma Co., Ltd., Zhongshan, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Shun Ma","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shun Ma","raw_affiliation_strings":["Chemical Manufacturing and Control Department, Akeso Biopharma Co., Ltd., Zhongshan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemical Manufacturing and Control Department, Akeso Biopharma Co., Ltd., Zhongshan, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059647302","display_name":"Xinrong He","orcid":"https://orcid.org/0000-0003-3426-1420","observed_orcids":["https://orcid.org/0000-0003-3426-1420"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xinrong He","raw_affiliation_strings":["Chemical Manufacturing and Control Department, Akeso Biopharma Co., Ltd., Zhongshan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemical Manufacturing and Control Department, Akeso Biopharma Co., Ltd., Zhongshan, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109525626","display_name":"Dennis Xia","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dennis Xia","raw_affiliation_strings":["Manufacturing and Quality Department, Akeso Biopharma Co., Ltd., Zhongshan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Manufacturing and Quality Department, Akeso Biopharma Co., Ltd., Zhongshan, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102836891","display_name":"Max Wang","orcid":"https://orcid.org/0000-0003-2121-9848","observed_orcids":["https://orcid.org/0000-0003-2121-9848"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Max Wang","raw_affiliation_strings":["Procurement and Sourcing Department and Clinical Operation Department, Akeso Biopharma Co., Ltd., Zhongshan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Procurement and Sourcing Department and Clinical Operation Department, Akeso Biopharma Co., Ltd., Zhongshan, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075723177","display_name":"Michelle Xia","orcid":"https://orcid.org/0000-0002-5137-2002","observed_orcids":["https://orcid.org/0000-0002-5137-2002"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michelle Xia","raw_affiliation_strings":["Akeso Biopharma Co., Ltd., Zhongshan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Akeso Biopharma Co., Ltd., Zhongshan, China","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5074582238","display_name":"Baiyong Li","orcid":"https://orcid.org/0009-0002-2426-9656","observed_orcids":["https://orcid.org/0009-0002-2426-9656"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Baiyong Li","raw_affiliation_strings":["Research and Development Department, Akeso Biopharma Co., Ltd., Zhongshan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development Department, Akeso Biopharma Co., Ltd., Zhongshan, China","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5074582238"],"corresponding_institution_ids":[],"apc_list":{"value":2950,"currency":"USD","value_usd":2950},"apc_paid":{"value":2950,"currency":"USD","value_usd":2950},"fwci":3.8356,"has_fulltext":true,"cited_by_count":44,"citation_normalized_percentile":{"value":0.95697732,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":95,"max":99},"biblio":{"volume":"13","issue":null,"first_page":"924542","last_page":"924542"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9053000211715698,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9053000211715698,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.09220000356435776,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/penpulimab","display_name":"penpulimab","score":1.0},{"id":"https://openalex.org/keywords/anti-pd-1-antibody","display_name":"anti-PD-1","score":0.9599999785423279},{"id":"https://openalex.org/keywords/fc-engineered-antibody","display_name":"Fc-engineered antibody","score":0.6959999799728394},{"id":"https://openalex.org/keywords/igg4-antibodies","display_name":"IgG4 antibodies","score":0.4830000102519989},{"id":"https://openalex.org/keywords/fcgamma-receptor-binding","display_name":"Fc\u03b3 receptor binding","score":0.781000018119812},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.8610000014305115},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-phagocytosis","display_name":"antibody-dependent cellular phagocytosis","score":0.9449999928474426},{"id":"https://openalex.org/keywords/antibody-stability","display_name":"antibody stability","score":0.5509999990463257},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.9829999804496765},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.5770000219345093},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.640999972820282},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.6460000276565552}],"concepts":[{"id":"https://openalex.org/C40677261","wikidata":"https://www.wikidata.org/wiki/Q21418091","display_name":"Antibody-dependent cell-mediated cytotoxicity","level":4,"score":0.9221307039260864},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.7024084329605103},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.6368082761764526},{"id":"https://openalex.org/C106847996","wikidata":"https://www.wikidata.org/wiki/Q898756","display_name":"Surface plasmon resonance","level":3,"score":0.5548266172409058},{"id":"https://openalex.org/C164027704","wikidata":"https://www.wikidata.org/wiki/Q3491837","display_name":"Proinflammatory cytokine","level":3,"score":0.5546923875808716},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5219047665596008},{"id":"https://openalex.org/C195616568","wikidata":"https://www.wikidata.org/wiki/Q128711","display_name":"Epitope","level":3,"score":0.4949299693107605},{"id":"https://openalex.org/C9086966","wikidata":"https://www.wikidata.org/wiki/Q489135","display_name":"Paratope","level":4,"score":0.4817926287651062},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.45615166425704956},{"id":"https://openalex.org/C2780898057","wikidata":"https://www.wikidata.org/wiki/Q79448","display_name":"Immunoglobulin G","level":3,"score":0.4106990396976471},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.35674750804901123},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.3167904019355774},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.24098560214042664},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.23806080222129822},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.23196813464164734},{"id":"https://openalex.org/C192562407","wikidata":"https://www.wikidata.org/wiki/Q228736","display_name":"Materials science","level":0,"score":0.16608890891075134},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.1023089587688446},{"id":"https://openalex.org/C171250308","wikidata":"https://www.wikidata.org/wiki/Q11468","display_name":"Nanotechnology","level":1,"score":0.06936559081077576},{"id":"https://openalex.org/C155672457","wikidata":"https://www.wikidata.org/wiki/Q61231","display_name":"Nanoparticle","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000920","descriptor_name":"Antibody-Dependent Cell Cytotoxicity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007074","descriptor_name":"Immunoglobulin G","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D015994","descriptor_name":"Incidence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016207","descriptor_name":"Cytokines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.3389/fimmu.2022.924542","doi":"https://doi.org/10.3389/fimmu.2022.924542","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2022.924542","pdf_url":null,"source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:9272907","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9272907","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Immunol","raw_type":"Text"},{"id":"pmid:35833116","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35833116","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in immunology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:ac47a7c60d1f4502a8af848e72115466","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/ac47a7c60d1f4502a8af848e72115466","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Immunology, Vol 13 (2022)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fimmu.2022.924542","doi":"https://doi.org/10.3389/fimmu.2022.924542","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2022.924542","pdf_url":null,"source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":49,"referenced_works":["https://openalex.org/W145329232","https://openalex.org/W1182461782","https://openalex.org/W1587403680","https://openalex.org/W1912738970","https://openalex.org/W1950618346","https://openalex.org/W1999596528","https://openalex.org/W2053429933","https://openalex.org/W2075027825","https://openalex.org/W2092921437","https://openalex.org/W2125616358","https://openalex.org/W2135611522","https://openalex.org/W2143649531","https://openalex.org/W2146146606","https://openalex.org/W2149532361","https://openalex.org/W2150048477","https://openalex.org/W2158633610","https://openalex.org/W2160834915","https://openalex.org/W2164143412","https://openalex.org/W2171756567","https://openalex.org/W2229885885","https://openalex.org/W2257999935","https://openalex.org/W2258069830","https://openalex.org/W2314289243","https://openalex.org/W2335217992","https://openalex.org/W2409911851","https://openalex.org/W2473759462","https://openalex.org/W2530034556","https://openalex.org/W2560367415","https://openalex.org/W2572174216","https://openalex.org/W2586232813","https://openalex.org/W2612649234","https://openalex.org/W2726507447","https://openalex.org/W2739147542","https://openalex.org/W2741635751","https://openalex.org/W2743419024","https://openalex.org/W2796970920","https://openalex.org/W2799565954","https://openalex.org/W2811001941","https://openalex.org/W2891951654","https://openalex.org/W2904099327","https://openalex.org/W2923429143","https://openalex.org/W3020886383","https://openalex.org/W3021646013","https://openalex.org/W3043584880","https://openalex.org/W3080326689","https://openalex.org/W3167228154","https://openalex.org/W3201742374","https://openalex.org/W3203111497","https://openalex.org/W4206209930"],"related_works":["https://openalex.org/W3203111497","https://openalex.org/W3111336849","https://openalex.org/W4308398376","https://openalex.org/W3104833405","https://openalex.org/W7213349696","https://openalex.org/W4284713527","https://openalex.org/W4400063678","https://openalex.org/W4392189073","https://openalex.org/W4399761779","https://openalex.org/W3214156611"],"abstract_inverted_index":{"Background":[0],"IgG4":[1,169],"anbibodies":[2],"are":[3],"deficient":[4],"in":[5,103,204,209],"stability":[6,158,265],"and":[7,50,66,71,86,95,99,106,129,159,184,190,193,198,222,266,292],"may":[8,296],"contribute":[9,297],"to":[10,31,122,180,213,215,277,298],"tumor-associated":[11],"escape":[12],"from":[13,111,141,227,252],"immune":[14],"surveillance.":[15],"We":[16],"developed":[17],"an":[18],"IgG1":[19,257],"backbone":[20,170,258],"anti-programmed":[21],"cell":[22,269],"death":[23,251],"protein-1":[24],"(PD-1)":[25],"antibody,":[26],"penpulimab,":[27],"which":[28,295],"is":[29],"designed":[30],"remove":[32],"crystallizable":[33],"fragment":[34],"(Fc)":[35],"gamma":[36],"receptor":[37],"(Fc\u03b3R)":[38],"binding":[39,179,276],"that":[40],"mediates":[41],"antibody-dependent":[42,46,107],"cell-mediated":[43],"cytotoxicity":[44],"(ADCC),":[45],"cellular":[47,104],"phagocytosis":[48],"(ADCP)":[49],"proinflammatory":[51],"cytokine":[52,108],"release.":[53],"Methods":[54],"Aggregation":[55],"of":[56,82,120,132,149,163,287],"different":[57],"anti-PD-1":[58,171],"antibodies":[59],"was":[60,114,125,134,207,254],"tested":[61],"by":[62,91,116,127,201],"size":[63],"exclusion":[64],"chromatography,":[65],"melting":[67],"temperature":[68,73],"midpoint":[69],"(Tm)":[70],"aggregation":[72],"onset":[74],"(Tagg)":[75],"were":[76,89,101,145,237],"also":[77],"determined.":[78],"The":[79],"affinity":[80],"constants":[81],"penpulimab":[83,121,175,261,288],"for":[84,147,239],"PD-1":[85,124,217,228],"human":[87,112,123,216],"Fc\u03b3Rs":[88],"measured":[90],"surface":[92],"plasmon":[93],"resonance":[94],"biolayer":[96],"interferometry.":[97],"ADCC":[98,189],"ADCP":[100,191,291],"determined":[102,126],"assays":[105],"release":[109,200],"(ADCR)":[110],"macrophages":[113,203],"detected":[115],"ELISA.":[117],"Binding":[118],"kinetics":[119],"Biacore,":[128],"epitope/paratope":[130],"mapping":[131],"PD-1/penpulimab":[133],"investigated":[135],"using":[136],"x-ray":[137],"crystallography.":[138],"Additionally,":[139],"patients":[140,236,243],"six":[142],"ongoing":[143],"trials":[144],"included":[146],"analysis":[148],"immune-related":[150],"adverse":[151],"events":[152],"(irAEs).":[153],"Results":[154],"Penpulimab":[155,206],"demonstrated":[156],"better":[157],"a":[160,224,263],"lower":[161],"level":[162],"host-cell":[164],"protein":[165,270],"residue":[166],"compared":[167],"with":[168],"antibodies.":[172],"As":[173],"expected,":[174],"exhibited":[176],"no":[177,187,195],"apparent":[178,188],"Fc\u03b3RIa,":[181],"Fc\u03b3RIIa_H131,":[182],"Fc\u03b3RIIIa_V158":[183],"Fc\u03b3RIIIa_F158,":[185],"elicited":[186],"activities,":[192],"induced":[194],"remarkable":[196],"IL-6":[197],"IL-8":[199],"activated":[202],"vitro.":[205],"shown":[208],"the":[210,278],"co-crystal":[211],"study":[212],"bind":[214],"N-glycosylation":[218],"site":[219],"at":[220],"N58":[221],"had":[223,244],"slower":[225],"off-rate":[226],"versus":[229],"nivolumab":[230],"or":[231,247],"pembrolizumab.":[232],"Four":[233],"hundred":[234],"sixty-five":[235],"analyzed":[238],"irAEs.":[240,249],"Fifteen":[241],"(3.2%)":[242],"grade":[245],"3":[246],"above":[248],"No":[250],"irAEs":[253],"reported.":[255],"Conclusions":[256],"anti-PD1":[259],"antibody":[260],"has":[262,282],"good":[264],"reduced":[267,293],"host":[268],"residue,":[271],"as":[272,274],"well":[273],"potent":[275],"antigen.":[279],"Fc":[280],"engineering":[281],"eliminated":[283],"Fc-mediated":[284],"effector":[285],"functions":[286],"including":[289],"ADCC,":[290],"ADCR,":[294],"its":[299],"more":[300],"favorable":[301],"safety":[302],"profile.":[303],"Clinical":[304],"Trial":[305],"Registration":[306],"www.ClinicalTrials.gov":[307],",":[308],"identifier:":[309],"AK105-101:":[310],"NCT03352531,":[311],"AK105-201:":[312],"NCT03722147,":[313],"AK105-301:":[314],"NCT03866980,":[315],"AK105-202:NCT03866967,":[316],"AK105-203:":[317],"NCT04172571,":[318],"AK105-204:":[319],"NCT04172506.":[320]},"counts_by_year":[{"year":2026,"cited_by_count":10},{"year":2025,"cited_by_count":9},{"year":2024,"cited_by_count":15},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-06-28T00:00:00"}